Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group.
Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group.
复制标题
在前列腺疾病的临床管理中使用症状评分、尿流率测定和前列腺特异性抗原的重复测量。
DOI：
10.1097/00005392-199501000-00036
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Guess,HA
中科院分区：
文献类型：
--
作者：
Barry,MJ;Girman,CJ;O'Leary,MP;Walker-Corkery,ES;Binkowitz,BS;Cockett,AT;Guess,HA
美国泌尿外科协会的症状评分、最大尿流率和前列腺特异性抗原(PSA)的测量在泌尿外科治疗中经常被跟踪一段时间。然而，由于偶然的原因，他们的解释被患者内部的可变性所混淆。来自2个临床试验的数据被用来检验这种变异的大小。当这些测量以短时间间隔重复时，变化不大，很容易被误解为患者病情的真正变化。例如，大约20%的患者可能预期症状评分有机会增加或减少至少4.9分，尿流率峰值至少每秒增加或减少4.1毫升，PSA至少增加1.6毫微克/毫升。临床医生可以使用这些数据来帮助解释患者对这些变量的重复测量，并可以考虑获得配对测量，以减少机会变化的影响，当他们计划随着时间的推移进行跟踪时。
Measurements of American Urological Association symptom score, peak urine flow rate and prostate specific antigen (PSA) are often followed over time in urological management. However, their interpretation is confounded by within-patient variability due to chance. Data from 2 clinical trials are used to examine the magnitude of this variation. When these measures are repeated at a short interval variation is modest and might easily be misinterpreted as a true change in patient condition. For example, approximately 20% of patients might be expected to have a chance increase or decrease in symptom score by at least 4.9 points, in peak urine flow rate by at least 4.1 ml. per second or in PSA by at least 1.6 ng./ml. Clinicians can use these data to help interpret repeated measures of these variables in patients, and can consider obtaining paired measurements to decrease the effect of chance variation when they plan on following them over time.